GABA-B agonist / phenyl-GABA

Plain-language summaryIntrigue 60 / 100

Phenibut is a Russian anxiolytic that activates GABA-B receptors (the same receptors as the prescription drug baclofen). It produces anxiolysis at low doses but carries dependence and severe withdrawal risk with regular use. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

29/100

Soviet-era GABA-B agonist with real anxiolytic signal but low novelty, dependence risk, and no Western trial base

Look, phenibut is a compound that’s been around since Khrushchev was in power, and that history cuts both ways. The 4-amino-3-phenylbutanoic acid structure is clever for its time: slap a phenyl group on GABA and suddenly you’ve got BBB penetration that GABA itself can’t achieve. That was genuinely interesting in 1964. It’s less interesting now.

The mechanism is GABA-B agonism, which puts it squarely in baclofen territory. Baclofen is the reference GABA-B agonist, well-characterized, cheap, and carrying a substantial clinical and preclinical literature. Phenibut’s distinguishing features are a different pharmacokinetic profile (5-6 hour half-life, rapid oral absorption) and its long history in Soviet and post-Soviet clinical practice across Russia, Belarus, Kazakhstan, and Latvia. But “different from baclofen” is a weak differentiator when baclofen is already the better-studied probe for the same receptor system. Some voltage-gated calcium channel activity shows up at higher concentrations, which is mildly interesting mechanistically, but it doesn’t reframe what this compound is doing.

The evidence base is real but messy. Decades of Russian-language clinical literature document use for anxiety, insomnia, and asthenia, and the compound is approved in multiple countries, which means at least some regulatory body looked at the data. Western replication is essentially absent, though. Russian clinical trials from that era are difficult to evaluate on methodological grounds, and thats not a criticism of the underlying science so much as an honest accounting of what investigators here can actually work with. No phase 2 or 3 Western RCTs. No multi-center replicated trials in English-language literature that hold up to modern scrutiny.

What we dont like: the dependence liability is substantial and well-documented. Withdrawal resembling benzodiazepine or baclofen discontinuation syndrome has been reported with chronic high-dose use, and that’s not a minor footnote. It limits research utility considerably for anything beyond acute or intermittent dosing paradigms, and it adds IRB and ethics complications that better-characterized alternatives simply don’t carry. The US regulatory status as an increasingly scrutinized research chemical adds sourcing friction on top of that.

As a bench tool, phenibut retains some utility for GABA-B CNS pharmacology, particularly for investigators who need a probe with a different kinetic profile than baclofen or want to study the (R)-enantiomer selectivity question in stereoselective receptor work. There’s a narrow research niche here. But if you’re building a GABA-B program, baclofen is still the standard reference compound, and phenibut is supplementary at best.

This isn’t a compound we’d prioritize for a library oriented toward frontier targets. The mechanism is mature, the evidence base is murky by Western standards, and the dependence liability introduces real practical constraints that blunt its value as a routine research tool. The score reflects a real compound with a real pharmacological effect that just doesn’t offer much that’s new to a serious investigator in 2025.

Novelty: 18
Mechanism promise: 25
In-category differentiation: 28
Evidence quality: 38
Translational signal: 42
Research bench value: 32

Rationale Phenibut’s mechanism is a known quantity (GABA-B agonism, baclofen-adjacent) and the compound has been in Eastern European clinical use since the 1960s, producing a mature but methodologically limited evidence base with no Western RCTs. Dependence liability and US regulatory gray-zone status further constrain its utility as a serious research tool.

GABA-B agonist / phenyl-GABA

A Soviet-developed phenyl-substituted GABA analog with GABA-B receptor agonism, used clinically in Russia for anxiety and sleep with documented dependence liability.

Abstract

Phenibut (4-amino-3-phenyl-butanoic acid; CAS 1078-21-3; molecular formula C10H13NO2; molecular weight 179.22) is a phenyl-substituted GABA analog developed in the Soviet Union in the 1960s at the Herzen State Pedagogical University. The phenyl substitution at the 3-position confers blood-brain barrier permeability that GABA itself lacks. Phenibut is approved in Russia, Belarus, Kazakhstan, and Latvia as Phenibut, Noofen, and Anvifen for anxiety, insomnia, asthenia, and post-traumatic stress disorder. Mechanism is primarily GABA-B receptor agonism (similar to baclofen) with secondary effects on voltage-gated calcium channels at higher doses. The (R)-enantiomer is the active component. Pharmacokinetics: plasma half-life 5 to 6 hours; rapid oral absorption. Doses are 250 to 1500 mg per day. Phenibut has documented dependence liability with chronic high-dose use; withdrawal syndrome includes anxiety, insomnia, tremor, and rebound symptoms. The compound is sold as a research chemical/dietary supplement in the United States though regulatory classification is increasingly restrictive in some states. Investigators should be aware of the dependence potential and avoid daily dosing schedules.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-067Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Tag: GABA-B agonist / phenyl-GABA

Phenibut

Abstract

Read the full monograph